Mylan NV

$ 26.68 0.24 (0.91%)
On watch
Volume: 3,710,194 Avg Vol (1m): 5,981,852
Market Cap $: 13.77 Bil Enterprise Value $: 27.10 Bil
P/E (TTM): 39.24 P/B: 1.13
Earnings Power Value 5.58
Net Current Asset Value -27.54
Tangible Book -21.81
Projected FCF 39.63
Median P/S Value 37.63
Graham Number 0
Peter Lynch Value 5.45
DCF (FCF Based) 0
DCF (Earnings Based) 0
YTD (-%)

Financial Strength : 4/10

Current vs industry vs history
Cash-to-Debt 0.04
Equity-to-Asset 0.37
Debt-to-Equity 1.14
Debt-to-EBITDA 4.68
Interest Coverage 1.58
Piotroski F-Score 5
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 1.15
DISTRESS
GREY
SAFE
Beneish M-Score -2.92
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 3.78%
WACC 7.35%

Profitability & Growth : 7/10

Current vs industry vs history
Operating Margin % 7.49
Net Margin % 3.08
ROE % 2.80
ROA % 1.03
ROC (Joel Greenblatt) % 20.56
3-Year Total Revenue Growth Rate 6.60
3-Year Total EBITDA Growth Rate 8.90
3-Year EPS w/o NRI Growth Rate -26.30
N/A

» MYL's 30-Y Financials

Financials (Next Earnings Date: 2019-05-09)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:MYL

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS : 325412    SIC : 2834
Compare TSE:4523 NSE:SUNPHARMA SHSE:600518 NYSE:TEVA TSE:4507 SZSE:000538 SHSE:600196 XPAR:IPN OCSE:LUN NYSE:PRGO TSE:4508 SZSE:000963 XSWX:VIFN SZSE:300122 JSE:APN SHSE:600332 HKSE:03320 SHSE:600085 TSE:4581 SHSE:600535
Traded in other countries 6MY.Germany MYL1.Switzerland 0R5P.UK
Address Building 4, Trident Place, Mosquito Way, Hatfield, Hertfordshire, GBR, AL10 9UL
Mylan is one of the world's largest generic pharmaceutical manufacturers with operations in the United States, Europe, Asia, Middle East, Africa, and Australia. Generic drug sales constitute approximately 90% of revenue. Remaining sales come from a handful of branded products, primarily epinephrine injector EpiPen. Mylan also owns Matrix, an Indian active pharmaceutical ingredient manufacturer.

Ratios

Current vs industry vs history
PE Ratio (TTM) 39.24
Forward PE Ratio 5.91
N/A
PE Ratio without NRI 39.24
Price-to-Owner-Earnings 11.04
PB Ratio 1.13
PS Ratio 1.20
Price-to-Free-Cash-Flow 12.03
Price-to-Operating-Cash-Flow 5.88
EV-to-EBIT 32.21
EV-to-EBITDA 9.17
EV-to-Revenue 2.37
PEG Ratio 5.48
Shiller PE Ratio 20.58
Current Ratio 1.39
Quick Ratio 0.83
Days Inventory 126.56
Days Sales Outstanding 77.14
Days Payable 55.16

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -1.70

Valuation & Return

Current vs industry vs history
Price-to-Projected-FCF 0.67
Price-to-Median-PS-Value 0.71
Price-to-Peter-Lynch-Fair-Value 4.90
Earnings Yield (Joel Greenblatt) % 3.10
Forward Rate of Return (Yacktman) % 15.67

More Statistics

Revenue (TTM) (Mil) $ 11,433.9
EPS (TTM) $ 0.68
Beta 1.66
Volatility % 32.94
52-Week Range $ 26 - 42.5
Shares Outstanding (Mil) 515.95

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 5
Positive ROA Y
Positive CFROA Y
Higher ROA yoy N
CFROA > ROA Y
Lower Leverage yoy N
Higher Current Ratio yoy Y
Less Shares Outstanding yoy Y
Higher Gross Margin yoy N
Higher Asset Turnover yoy N